This post has been read 24797 times!
KUWAIT CITY, Dec 23, (Agencies): Two new British studies provide some early hints that the omicron variant of the coronavirus may be milder than the delta version. Scientists stress that even if the findings of these early studies hold up, any reductions in severity need to be weighed against the fact Omicron spreads much faster than delta and is more able to evade vaccines. Sheer numbers of infections could still overwhelm hospitals. Still, the new studies released Wednesday seem to bolster earlier research that suggests Omicron may not be as harmful as the delta variant, said Manuel Ascano Jr., a Vanderbilt University biochemist who studies viruses. “Cautious optimism is perhaps the best way to look at this,” he said.
An analysis from the Imperial College London COVID-19 response team estimated hospitalization risks for Omicron cases in England, finding people infected with the variant are around 20% less likely to go to the hospital at all than those infected with the delta variant, and 40% less likely to be hospitalized for a night or more. That analysis included all cases of COVID-19 confirmed by PCR tests in England in the first half of December in which the variant could be identified: 56,000 cases of Omicron and 269,000 cases of delta.
A separate study out of Scotland, by scientists at the University of Edinburgh and other experts, suggested the risk of hospitalization was two-thirds less with Omicron than delta. But that study pointed out that the nearly 24,000 Omicron cases in Scotland were predominantly among younger adults ages 20 to 39. Younger people are much less likely to develop severe cases of COVID- 19. “This national investigation is one of the first to show that Omicron is less likely to result in COVID-19 hospitalization than delta,” researchers wrote. While the findings are early observations, “they are encouraging,” the authors wrote. The findings have not yet been reviewed by other experts, the gold standard in scientific research.
Ascano noted the studies have limitations. For example, the findings are specific to a certain point in time during a quickly changing situation in the United Kingdom and other countries may not fare the same way. Matthew Binnicker, director of clinical virology at Mayo Clinic in Rochester, Minnesota, said that in the Scottish study, the percentage of younger people was almost twice as high for the Omicron group compared with the delta group, and that “could have biased the conclusions to less severe outcomes caused by Omicron.”
He nonetheless said the data were interesting and suggest Omicron might lead to less severe disease. But he added: “It’s important to emphasize that if Omicron has a much higher transmission rate compared to delta, the absolute number of people requiring hospitalization might still increase, despite less severe disease in most cases.” Data out of South Africa, where the variant was first detected, have also suggested Omicron might be milder there. Salim Abdool Karim, a clinical infectious disease epidemiologist in South Africa, said earlier this week that the rate of admissions to hospitals was far lower for Omicron than it was for delta. “Our overall admission rate is in the region of around 2% to 4% compared to previously, where it was closer to 20%,” he said.
“So even though we’re seeing a lot of cases, very few are being admitted.” U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-touse medication to battle the rising tide of omicron infections. The Food and Drug Administration authorization of Merck’s molnupiravir comes one day after the agency cleared a competing drug from Pfizer. That pill, Paxlovid, is likely to become the first-choice treatment against the virus, thanks to its superior benefits and milder side effects.
As a result, Merck’s pill is expected to have a smaller role against the pandemic than predicted just a few weeks ago. Its ability to head off severe COVID- 19 is much smaller than initially announced and the drug label will warn of serious safety issues, including the potential for birth defects. The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. The U.K. first authorized the pill in early November.
Known as molnupiravir, the Merck drug will carry a warning against use during pregnancy. Women of childbearing age should use birth control during treatment and for a few days after while men should use birth control for at least three months after their final dose, the FDA said.